non-alcoholic fatty liver disease

(redirected from Nonalcoholic Fatty Liver Disease)
Also found in: Acronyms.

non-alcoholic fatty liver disease

A fatty liver lacking histologic features typically associated with alcohol abuse, which primarily affects overweight women. With time, patients develop portal changes such as interface hepatitis, increased portal inflammation and fibrosis, and autoantibodies.
 
Risk factors
Diabetes, obesity, hypertension, gallstones, hyperlipidaemia, hypertriglyceridaemia.

Pathogenesis
Uncertain; possibly oxidative stress and lack of antioxidants.

Non-alcoholic fatty liver disease types
• Steatosis;
• Steatosis with inflammation;
• Non-alcoholic steatohepatitis (NASH);
• Cirrhosis.
Mentioned in ?
References in periodicals archive ?
About Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and it affects almost 30% of adults in Western countries.
In an article discussing findings of this study and interpreting their meaning, an HIV-liver expert predicted that nonalcoholic fatty liver disease and NASH "will likely become the dominant liver disease among HIV-infected persons" because treatment of HCV infection has improved dramatically in recent years.
Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease.
The researchers added BMI to their multivariate analysis to determine whether women with a gestational diabetes history gained more weight, and whether that weight explained the increased prevalence of NAFLD, "and found that the association between gestational diabetes and nonalcoholic fatty liver disease remained," Dr.
A through C, Case of nonalcoholic fatty liver disease (NAFLD) with steatohepatitic hepatocellular carcinoma (SH-HCC).
Nonalcoholic fatty liver disease is an increasingly prevalent clinical syndrome associated with obesity and type-2 diabetes mellitus, which is estimated to affect one-third of the general adult population in the USA.
Diagnostic value of biochemical markers(Fibro Test- Fibro SURE) for the prediction of liver fibrosis in patients with nonalcoholic fatty liver disease.
The results could have implications for treating many diseases, including diabetes, insulin resistance, and nonalcoholic fatty liver disease.
Also discussed are bariatric surgery, weight management, nonalcoholic fatty liver disease, obesity and gastrointestinal cancer, the role of macro and micronutrients in preventing colon cancer, nutrition and dietary supplements in inflammatory bowel disease, and small intestine transplantation.
Animal studies have indicated that adiponectin confers protection against alcoholic and nonalcoholic fatty liver disease (16) and that administration of adiponectin alleviated non-alcoholic fatty liver disease in mice (16).
The latest study tested it for nonalcoholic fatty liver disease.